Preferred Label : Anti-CD20/CD37 Monoclonal Antibody Combination PSB202;
NCIt synonyms : Anti-CD20/Anti-CD37 Monoclonal Antibody Combination PSB202; PSB102 Plus PSB107; PSB102/PSB107; Anti-CD20 Monoclonal Antibody/Anti-CD37 Monoclonal Antibody Combination PSB202; PSB102 and PSB107;
NCIt definition : A combination agent composed of two humanized monoclonal antibodies, PSB102, an Fc-enhanced
immunoglobulin G1 (IgG1) monoclonal antibody directed against the human B-cell-specific
cell surface antigen and tumor-associated antigen (TAA) CD20, and PSB107, an IgG1
monoclonal antibody directed against the TAA CD37, with potential immunomodulating
and antineoplastic activities. Upon administration, anti-CD20/CD37 monoclonal antibody
combination PSB202 specifically targets and binds to CD20 and CD37 expressed on tumor
cells. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC) against CD20- and CD37-expressing B-cells, which leads to B-cell
apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated
cell surface phosphoprotein that is exclusively expressed on B-cells during most stages
of B-cell development, is often overexpressed in B-cell malignancies. CD37, a member
of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety
of cancer cell types and plays a key role in tumor cell proliferation.;
Molecule name : PSB-202; PSB 202;
NCI Metathesaurus CUI : CL1794000;
Origin ID : C188957;
UMLS CUI : C5706517;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
